Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.

Serruys, Patrick W; Takahashi, Kuniaki; Chichareon, Ply; Kogame, Norihiro; Tomaniak, Mariusz; Modolo, Rodrigo; Chang, Chun Chin; Komiyama, Hidenori; Soliman, Osama; Wykrzykowska, Joanna J; de Winter, Robbert J; Ferrario, Maurizio; Dominici, Marcello; Buszman, Paweł; Bolognese, Leonardo; Tumscitz, Carlo; Benit, Edouard; Stoll, Hans-Peter; Hamm, Christian; Steg, Philippe Gabriel; ... (2019). Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European heart journal, 40(31), pp. 2595-2604. Oxford University Press 10.1093/eurheartj/ehz453

[img] Text
2019_Eur Heart J_Serruys_Impact of long-term ticagrelor monotherapy following 1 month.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

AIMS  To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin monotherapy following 12-month DAPT) after complex percutaneous coronary intervention (PCI). METHODS AND RESULTS In the present post hoc analysis of the Global Leaders trial, the primary endpoint [composite of all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with complex PCI, which includes at least one of the following characteristics: multivessel PCI, ≥3 stents implanted, ≥3 lesions treated, bifurcation PCI with ≥2 stents, or total stent length >60 mm. In addition, patient-oriented composite endpoint (POCE) (composite of all-cause death, any stroke, any MI, or any revascularization) and net adverse clinical events (NACE) [composite of POCE or Bleeding Academic Research Consortium (BARC) Type 3 or 5 bleeding] were explored. Among 15 450 patients included in this analysis, 4570 who underwent complex PCI had a higher risk of ischaemic and bleeding events. In patients with complex PCI, the experimental strategy significantly reduced risks of the primary endpoint [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.48-0.85] and POCE (HR: 0.80, 95% CI: 0.69-0.93), but not in those with non-complex PCI (Pinteraction = 0.015 and 0.017, respectively). The risk of BARC Type 3 or 5 bleeding was comparable (HR: 0.97, 95% CI: 0.67-1.40), resulting in a significant risk reduction in NACE (HR: 0.80, 95% CI: 0.69-0.92; Pinteraction = 0.011). CONCLUSION  Ticagrelor monotherapy following 1-month DAPT could provide a net clinical benefit for patients with complex PCI. However, in view of the overall neutral results of the trial, these findings of a post hoc analysis should be considered as hypothesis generating.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan and Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1522-9645

Publisher:

Oxford University Press

Language:

English

Submitter:

Amanda Valle

Date Deposited:

30 Aug 2019 14:47

Last Modified:

24 Oct 2019 23:32

Publisher DOI:

10.1093/eurheartj/ehz453

PubMed ID:

31397487

Uncontrolled Keywords:

Complex percutaneous coronary intervention Drug-eluting stent Dual antiplatelet therapy Ticagrelor monotherapy

BORIS DOI:

10.7892/boris.132769

URI:

https://boris.unibe.ch/id/eprint/132769

Actions (login required)

Edit item Edit item
Provide Feedback